<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01853033</url>
  </required_header>
  <id_info>
    <org_study_id>M14-048</org_study_id>
    <nct_id>NCT01853033</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>A Study in Patients With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ABT-122</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and pharmacokinetics of
      ABT-122 in subjects with Rheumatoid Arthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose
      study. Twenty-four subjects with Rheumatoid Arthritis will be selected to participate.
      Subjects will be randomized to receive either ABT-122 or placebo. ABT-122 or placebo will be
      administered as subcutaneous (under the skin) injections in three dosing groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>From date of first dose of ABT-122 until 42 days after the last dose of ABT-122</time_frame>
    <description>Collect all adverse events at each visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in physical exam including vital signs</measure>
    <time_frame>From date of first dose of ABT-122 until 42 days after last dose of ABT-122</time_frame>
    <description>Blood pressure, pulse and body temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in clinical lab test results</measure>
    <time_frame>From date of first dose of ABT-122 until 42 days after the last dose of ABT-122</time_frame>
    <description>Hematology, Chemistry, and Urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Electrocardiogram (ECG) results</measure>
    <time_frame>From subject's baseline (prior to subject's first dose) and up to 168 hours following the last dose of study drug</time_frame>
    <description>ECGs done in triplicate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of pharmacokinetic (PK) parameters</measure>
    <time_frame>Prior to first dose up to 42 days after the last dose of ABT-122</time_frame>
    <description>Cmax, Tmax, AUC, elimination rate constant and half-life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of anti-drug anti-bodies (ADA) of ABT-122</measure>
    <time_frame>Prior to each dose and up until 42 days after the last dose of ABT-122</time_frame>
    <description>Measurement of ADA</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized 6 drug/2 placebo by group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized 6 drug/2 placebo by group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized 6 drug/2 placebo by group</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ABT-122</intervention_name>
    <description>Injection</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Injection</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Rheumatoid Arthritis (RA) &gt; 3 months.

          -  On methotrexate (MTX) therapy =&gt; 3 months and on a stable dose for at least 4 weeks.

          -  Except for MTX, must have discontinued all disease-modifying antirheumatic drugs
             (DMARDs) for at least 3 months or 5 half-lives, whichever is longer.

          -  Body Mass Index (BMI) is 19 to 38, inclusive.

          -  Other than RA, subjects should be in good general health.

        Exclusion Criteria:

          -  Evidence of anti-ABT-122 antibody on a serum sample taken at Screening.

          -  History of significant allergic reaction; or history of anaphylactic reaction to any
             agent; or history of major reaction to any IgG containing product.

          -  History of persistent chronic or active infection(s) requiring hospitalization or
             treatment with intravenous or oral anti-microbials/antibiotics within the past 30
             days.

          -  History or evidence of active tuberculosis (TB) or the subject has evidence of risk
             factor for latent TB.

          -  Subject has any medical condition or illness other than RA that is not well controlled
             with treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Padley, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 108655</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 107115</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 118964</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 100780</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Khatri A, Goss S, Jiang P, Mansikka H, Othman AA. Pharmacokinetics of ABT-122, a TNF-Î±- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials. Clin Pharmacokinet. 2018 May;57(5):613-623. doi: 10.1007/s40262-017-0580-y.</citation>
    <PMID>28744796</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2013</study_first_submitted>
  <study_first_submitted_qc>May 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2013</study_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tolerability</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Safety</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

